Long-term therapeutic strategies in HIV

被引:8
作者
Miles, SA
机构
[1] University of California, Los Angeles, Center for Clinical AIDS Research and Education (CARE), Los Angeles, CA
[2] Clinical AIDS Research and Education (CARE) Clinic, University of California, Los Angeles, Los Angeles, CA 90095-1793
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1997年 / 16卷
关键词
antiretroviral therapy; HIV; AIDS; nucleoside analogues; non-nucleoside analogues; protease inhibition; cytokines; fatigue; oncology model;
D O I
10.1097/00042560-199701001-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Advances in the management of human immunodeficiency virus (HIV) disease, including the use of potent combination antiretroviral regimens, has greatly improved the outlook for patients with AIDS. Because HIV patients can now survive for extended periods, clinicians need to develop rational plans for long-term therapy that recognize the impact of such therapy on the patient. There are many similarities between cancer and HIV disease and an oncologic model can be used to design treatment plans for HIV. A successful plan fur long-term management of HIV involves establishing the diagnosis and extent of disease; determining the concerns of the patient as they relate to specific life goals and quality-of-life issues; identifying antiretroviral regimens for initial therapy, salvage therapy: and terminal or experimental therapy; and implementing the plan using clear parameters to evaluate the response to therapy. Tremendous strides have been made in managing HIV disease. It is now time to advance our management of the patients' concerns.
引用
收藏
页码:S36 / S41
页数:6
相关论文
共 25 条
[11]   A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter [J].
Hammer, SM ;
Katzenstein, DA ;
Hughes, MD ;
Gundacker, H ;
Schooley, RT ;
Haubrich, RH ;
Henry, WK ;
Lederman, MM ;
Phair, JP ;
Niu, M ;
Hirsch, MS ;
Merigan, TC ;
Blaschke, TF ;
Simpson, D ;
McLaren, C ;
Rooney, J ;
Salgo, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) :1081-1090
[12]   Viral dynamics of HIV: Implications for drug development and therapeutic strategies [J].
Havlir, DV ;
Richman, DD .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (11) :984-994
[13]   RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].
HO, DD ;
NEUMANN, AU ;
PERELSON, AS ;
CHEN, W ;
LEONARD, JM ;
MARKOWITZ, M .
NATURE, 1995, 373 (6510) :123-126
[14]   TIME TO HIT HIV, EARLY AND HARD [J].
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (07) :450-451
[15]   Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients - A randomized controlled comparison with zidovudine monotherapy [J].
Katlama, C ;
Ingrand, D ;
Loveday, C ;
Clumeck, N ;
Mallolas, J ;
Staszewski, S ;
Johnson, M ;
Hill, AM ;
Pearce, G ;
McDade, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02) :118-125
[16]   Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [J].
Mellors, JW ;
Rinaldo, CR ;
Gupta, P ;
White, RM ;
Todd, JA ;
Kingsley, LA .
SCIENCE, 1996, 272 (5265) :1167-1170
[17]   QUANTITATION OF HIV-1 RNA IN PLASMA PREDICTS OUTCOME AFTER SEROCONVERSION [J].
MELLORS, JW ;
KINGSLEY, LA ;
RINALDO, CR ;
TODD, JA ;
HOO, BS ;
KOKKA, RP ;
GUPTA, P .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (08) :573-579
[18]  
MELLORS JW, 1996, INFECT MED SF, V13, P32
[19]   Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS [J].
OBrien, WA ;
Hartigan, PM ;
Martin, D ;
Esinhart, J ;
Hill, A ;
Benoit, S ;
Rubin, M ;
Lahart, C ;
Wray, N ;
Finegold, SM ;
George, WL ;
Dickinson, GM ;
Klimas, N ;
Diamond, G ;
ZollaPazner, SB ;
Jensen, PC ;
Hawkes, C ;
Oster, C ;
Gordin, F ;
Labriola, AM ;
Spivey, P ;
Matthews, T ;
Weinhold, K ;
Drusano, G ;
Egorin, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (07) :426-431
[20]  
POLLARD R, 1996, P 3 C RETR OPP INF, P197